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Abstract
Background: Due to increasing drug resistance, artemisinin-based combination chemotherapy (ACT) has
become the first-line treatment of falciparum malaria in many endemic countries. However, irreversible
ototoxicity associated with artemether/lumefantrine (AL) has been reported recently and suggested to be
a serious limitation in the use of ACT. The aim of the study was to compare ototoxicity, tolerability, and
efficacy of ACT with that of quinine and atovaquone/proguanil in the treatment of uncomplicated
falciparum malaria.
Methods: Ninety-seven patients in south-west Ethiopia with slide-confirmed malaria were randomly
assigned to receive either artemether/lumefantrine or quinine or atovaquone/proguanil and followed-up
for 90 days. Comprehensive audiovestibular testing by pure tone audiometry (PTA), transitory evoked
(TE) and distortion product (DP) otoacoustic emissions (OAE) and brain stem evoked response
audiometry (BERA) was done before enrolment and after seven, 28 and 90 days.
Results: PTA and DP-OAE levels revealed transient significant cochlear hearing loss in patients treated
with quinine but not in those treated with artemether/lumefantrine or atovaquone/proguanil. TE-OAE
could be elicited in all examinations, except for three patients in the Q group on day 7, who suffered a
transient hearing loss greater than 30 dB. There was no evidence of drug-induced brain stem lesions by
BERA measurements.
Conclusion: There was no detrimental effect of a standard oral regimen of artemether/lumefantrine on
peripheral hearing or brainstem auditory pathways in patients with uncomplicated falciparum malaria. In
contrast, transient hearing loss is common after quinine therapy and due to temporary outer hair cell
dysfunction.
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Background
Resistance to antimalarial drugs is a common challenge in
malaria endemic areas worldwide. Due to increasing
resistance of Plasmodium falciparum strains against chloro-
quine and sulphadoxine/pyrimethamine, several Asian
and African countries have changed their national policy
towards first-line treatment with artemisinin-based com-
bination chemotherapies (ACT) as recommended by cur-
rent WHO guidelines [1,2].
Some case reports [3,4] as well as a recent alarming report
on the possibility of irreversible ototoxicity of artemether/
lumefantrine in a retrospective evaluation of construction
site workers in Mozambique [5] have raised concerns that
this potentially serious side effect of ACT has not been
addressed thoroughly enough, although no evidence of
neurological side effects or ototoxicity has been observed
in human safety studies or large-scale field trials [6] and
case control studies [7-9].
Ototoxicity has been reported in association with the use
of quinoline type antimalarials [10,11], and quinine since
long is known to cause reversible hearing loss and tinni-
tus[12]. Ototoxic effects have not been reported with the
use of some other antimalarials in current use, such as
atovaquone/proguanil.
To clarify the question of artemisinin-induced hearing
loss, this study integrated a comprehensive neuro-oto-
logic assessment into an investigator-initiated, open-
label, randomized, controlled study to compare arte-
mether/lumefantrine with quinine and atovaquone/pro-
guanil in the treatment of uncomplicated falciparum
malaria.
Methods
Study area and population
The study was carried out at Jimma University (JU) Hos-
pital in the city of Jimma, 1,700 m above sea level and 335
km south west of Addis Ababa, Ethiopia. In this region,
malaria transmission is seasonal with peaks from April to
June and from September to December during and after
the rainy seasons [13]. The first-line treatment of uncom-
plicated falciparum malaria changed from sulphadoxine/
pyrimethamine to AL in Ethiopia in 2004 [14]. Since the
drug has not yet been available until recently, oral quinine
has mainly been used instead.
Patients over five years of age and suitable for complete
audiovestibular testing with parasitologically proven
uncomplicated falciparum malaria were recruited from
April until August 2006. Uncomplicated falciparum
malaria was defined as asexual parasitaemia of less than
100,000/μl blood, acute fever or a history of fever within
the preceding 24 hours, and no signs or symptoms sug-
gesting complicated or severe malaria as defined by WHO
[15]. Patients with significant hearing loss as determined
by failure to detect transitory evoked otoacoustic emis-
sions in either ear, intake of anti-malarial treatment
within the previous seven days, severe underlying condi-
tions or concomitant disease masking assessment of
response, history of allergy or intolerance against study
medications, or pregnancy were excluded. Audiometric
testing (duration 1–1.5 h) of eligible patients at enrol-
ment was completed before starting antimalarial treat-
ment.
The study was approved by the Ethical Committee of
Jimma University, Ethiopia. Written informed consent
was obtained from each patient or the parental guide. Per-
sonal subject data are kept confidential. The trial is regis-
tered with ClinicalTrials.gov, number NCT00451139. The
recommendations guiding physicians in biomedical
research involving human subjects issued by the World
Medical Association Declaration of Helsinki (Edinburgh,
2000) were applied to this project.
Antimalarial drug regimens
Eligible patients were consecutively stratified according to
gender and age and assigned to one of the following treat-
ment groups by stratified random sampling:
1. Artemether/lumefantrine (AL): 20 mg of artemether
and 120 mg of lumefantrine (children 5–14 kg bwt.) or 40
mg/240 mg (children 15–24 kg bwt.) or 60 mg/360 mg
(children 25–34 kg bwt.) or 80 mg/480 mg (adults and
children ≥35 kg bwt.), at hrs. 0, 8, 24, 36, 48 and 60 (6
doses). Patients were instructed to take the doses with
high fat food.
2. Quinine sulphate (Q): 10 mg/kg (children) or 600 mg
(adults and children ≥50 kg bwt.), according to about 8
mg/kg Quinine base, three times daily for 7 days (21
doses).
3. Atovaquone/proguanil (AP): 20 mg/8 mg/kg (children
< 40 kg bwt.) or 1000 mg/400 mg (adults and children
≥40 kg bwt.) per day for 3 days (3 doses).
Artemether/lumefantrine 20/120 mg tablets (Coartem®,
Novartis, manifactured by Bejing Novartis Pharma Ltd,
Bejing China) and quinine sulphate 300 mg tablets
(Remedica Ltd, Limassol-Cyprus-Europe) were obtained
from the Ethiopian governmental drug programme
through the JU hospital pharmacy. Blister packs of
atovaquone/proguanil (Malarone®) were purchased from
GSK, Germany.Malaria Journal 2008, 7:179 http://www.malariajournal.com/content/7/1/179
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Procedures
Patients were treated on an outpatient basis and returned
on day 7, 28 and 90 and on any day during the follow-up
period if symptoms returned. Clinical reassessments cov-
ered assessments for potential treatment failure and for
potential adverse reactions to the treatment drug includ-
ing complete audiovestibular testing.
Finger prick blood samples were taken at day 0 for confir-
mation of P. falciparum mono-infection and calculation of
parasitaemia (parasites per 200 white blood cells, calcula-
tion based on an assumed mean WBC count of 8,000/ml)
by microscopic assessment of Giemsa-stained thick and
thin blood smears. Aliquots of 10 μl of capillary blood
were spotted to Whatman 3 MM Chr filter paper, air dried,
and stored at ambient temperature for later molecular
analysis. Follow-up blood samples were obtained at days
7 and 28 as well as on any day of potential clinical treat-
ment failure. Patients with falciparum or vivax malaria
during the follow-up period were treated according to
national guidelines [14]. These patients were excluded
from the study after treatment. Patients who completed
examinations on day 28 were included in the audiovestib-
ular analysis.
Audiovestibular tests were performed by an examiner
blinded to treatment allocation in a separate building spe-
cifically designated for this purpose. Although a sound-
proof chamber was not available, care was taken to reduce
ambient noise to a minimum (see below). Clinical audio-
vestibular evaluation at each visit included the history of
specific complaints (i.e., hearing loss, otalgia, tinnitus,
vertigo), otoscopy, Weber and Rinne tests, examination
for spontaneous and head-shaking nystagmus under Fren-
zel glasses, and testing the vestibular function by rapid
passive head rotation. Physical examination included gait,
Romberg and Unterberger test, finger-to-finger test, and
hand rapid alternating movements [16].
Pure tone audiometry was performed with a Madsen
Midimate 622D diagnostic audiometer (GN Otometrics,
Copenhagen, Denmark) and Beyer DT 48 headphones.
The thresholds for frequencies from 125 to 8000 Hz were
determined via air conduction. In addition, bone conduc-
tion thresholds for 250 to 6000 Hz were determined in
order to exclude conductive hearing loss.
In contrast to conventional audiometry, the detection of
otoacoustic emissions does not rely on the patients coop-
eration, and is an excellent indicator for physiologic inner
ear function. Transitory evoked (TE) and distortion prod-
uct (DP) otoacoustic emissions (OAE) were measured
with a Cochlea Scan® device (Fischer Zoth, Germering,
Germany). TEOAE were analysed using a screening proto-
col giving a pass (detectable TEOAE) vs. fail result.
DPOAE levels were measured at frequencies of f2 = 1.5, 2,
3, 4, 6 kHz with at least three different primary tone levels
per frequency between 15 and 65 dB (f2/f1 = 1.2). From
the resulting DPOAE growth functions, DP thresholds
and estimated hearing thresholds are calculated based on
normative data [17,18]. The average noise floor during
measurements was -1.2/-2.6/-4.1/-3.6/-3.5 dB for 1.5/2/
3/4/6 kHz.
Brain stem evoked response audiometry (BERA) examines
the velocity of nerve signal conduction along the auditory
pathways from the cochlea to the brainstem, and is the
gold standard for detection of damage to the participating
neural structures. The measurements were done using an
evoselect system (Pilot Blankenfelde, Blankenfelde, Ger-
many). The stimulus, a click of alternating polarity, was
delivered at a rate of 11.1 Hz at a level of 80 dB HL and
contralateral masking at 40 dB HL to patients resting in a
supine position. 2000 measurements were averaged and
the absolute and interpeak latencies of Jewett waves I, III
and V determined.
For molecular typing sample DNA was extracted from fil-
ter paper bloodspots using Chelexò (Bio-Rad, Germany)
as described elsewhere [19]. Parasite species was con-
firmed by nested polymerase chain reaction (PCR) [20].
Sequences of parasite genes coding for the polymorphic
merozoite surface proteins (MSP) 1 and 2 were amplified
by nested PCR and analysed by restriction fragment length
polymorphisms (RFLP) technique [21,22]. MSP1 and
MSP2 fragment patterns of isolates from patients with
parasite re-appearance were compared with those of the
respective recruitment isolates to distinguish recrudes-
cences from new infections [23].
Statistical analysis
A sample size of 23 in each group was calculated to have
90% power to detect a difference in means of 5.0 dB (e.g.,
the difference between a group 1 mean of 5.0 and a group
2 mean of 0.0) assuming that the common standard devi-
ation is 5.0 dB using a two group t-test with a 0.05 two-
sided significance level. In order to avoid problems with
the assumption of normal distribution and to compensate
for possible drop-outs it was decided to increase the sam-
ple size to at least 30 per group. Data were analysed using
SSPS 14.0 software for descriptive statistical analyses and
R package V2.4.0 for multivariate methods. The baseline
characteristics of the patients were compared by Kruskal-
Wallis test for variables that are measured on a continuous
scale or by Pearson Chi-square test for categorial variables.
The audiological data in a longitudinal setting were fitted
in mixed linear model approaches. Potential factors
included in the models were day after enrolment, therapy
group and side. Variables not significant on the 5% level
were sequentially eliminated from the models with excep-Malaria Journal 2008, 7:179 http://www.malariajournal.com/content/7/1/179
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tion of the therapy group. In case measurements of the left
and right side showed no significant differences, both val-
ues were treated in the models as repeating measure-
ments. Generally, a p value of < 0.05 was considered
significant.
Results
230 patients with suspected malaria were screened and
133 were excluded for various reasons (Figure 1). 97
patients were included and randomized. 30 patients
received AL, 35 Q, and 32 AP (Figure 1). Baseline charac-
teristics are given in Table 1. None of the patients had
received an artemisinin compound before. Cumulated
numbers of patients lost to follow-up were one at day 7,
four at day 28, and seven at day 90. Thirteen patients were
excluded due to recrudescence or new infection (Figure 1).
patient flow chart Figure 1
patient flow chart. Enrollment, randomization and follow-up of the patients. § The reasons for exclusion (number of 
patients) were ear discharge (20), impacted ear wax (18), repeated previous otitis media (14), perforated ear drum (6), nega-
tive TEOAE recording (15), Weber test lateralized (10), self-treatment with chloroquine (18), mixed infection (17), pregnancy 
(15). * Patients treated with a second course of antimalarials because of recrudescence or new infection were excluded from 
audiovestibular evaluation.Malaria Journal 2008, 7:179 http://www.malariajournal.com/content/7/1/179
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Table 1: Baseline characteristics of the patients who reached the primary end-point (day 28)
Quinine Atovaquone/Proguanil Artemether/Lumefantrine
n 30 30 30
sex m/f 16/14 16/14 18/12
age range 6 – 50 6 – 35 8 – 40
mean 19.2 19.9 18.1
median 16 18 17
Temperature (C°) range 36.0 – 39.5 36.0 – 39.3 35.6 – 39.9
mean 37.4 37.3 37.5
median 37.2 37.3 37.4
Parasitaemia range 360 – 63,000 400 – 69,880 480 – 83,600
mean 15,469 13,028 21,189
median 6,740 4,960 9,300
Symptoms Headache 30 30 30
Nausea/vomiting 21 17 22
Shivering 23 26 21
Diarrhea 4 2 3
Actual daily dose (mg/kg) range 30.5 – 36 15 – 23 2.3 – 4.6
mean 34.9 19.5 3.4
stdev 1.6 1.9 0.6
Baseline patients' characteristics of the patients who reached the primary end-point (day 28) were not significantly different between the three 
treatment groups in respect to age (Kruskal-Wallis-test, p = 0,504), sex (χ2-test, p = 0,835), parasitaemia (Kruskal-Wallis-test, p = 0,444), body 
temperature (Kruskal-Wallis-test, p = 0,860). There is also no significant difference in these baseline characteristics of the treatment groups when 
comparing all 97 treated patients.
Table 2: Clinical and parasitological efficacy
PCR-corrected failure rates A/L Quinine A/P
Clinical failure rate day 7 0/30 0/35 0/32
Parasitological failure rate day 7 0/30 0/35 0/32
Intention to treat failure rate* day 7 0/30 1/35 (~3%) 0/32
Clinical failure rate day 28 0/30 3/35 (~9%) 1/32 (~3%)
Parasitological failure rate day 28 0/30 3/35 (~9%) 2/32 (~6%)
Intention to treat failure rate* day 28 0/30 7/35 (~20%) 4/32 (~13%)
Recurrent parasitaemia
Number of patients with recrudescence** (day) 1 (70) 4 (24, 28, 28, 40***) 2 (28, 28)
Number of patients with new infection** (day) 1 (73) 4 (34, 40, 40***, 65) 1 (80)
Number of patients with P. vivax infection (day) 2 (28, 28) 5 (22, 25, 27, 28, 28) 2 (28, 28)
Gametocytaemia
Number of patients on day 0 1 3 1
Number of patients on day 7 2 10 16
Number of patients on day 28 0 2 0
* lost to follow-up included
**P. falciparum: Genotyping by PCR and RFLP patterns of the MSP-1 and MSP-2 gene
*** One sample showed two different clones on day 40, one of them corresponded to the clone on day 0.Malaria Journal 2008, 7:179 http://www.malariajournal.com/content/7/1/179
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Clinical and parasitological efficacy
On day 7 no treatment failure was detected in any group
(Table 2). Until day 28, three patients in the Q group and
one in the AP group presented with falciparum malaria.
Another patient with asymptomatic parasitaemia was
identified in the AP group. The parasitological failure rate
on day 28 was 9% and 6% in the Q and AP group, respec-
tively. There was no treatment failure in the AL group. All
treatment failures were recrudescences as confirmed by
genotyping.
Between day 28 and day 90 seven patients with falci-
parum malaria were diagnosed. Five patients had a new
infection. A recrudescent and a new strain were found in a
patient in the Q group on day 40, and one recrudescence
occurred on day 70 in the AL group.
Nine patients (five treated with Q, two with AP, and two
with AL) showed P. vivax infection during follow-up
(Table 2).
Tolerability and ototoxicity assessment
No vomiting occurred after ingestion of the antimalarial
drugs, and no serious adverse events were reported during
treatment and follow-up. Most symptoms present at the
time of diagnosis resolved until day 7 (Table 3). However,
hearing problems and tinnitus were more common on
day 7 with nine of thirty patients complaining of hearing
problems in the Q group. In seven of these, audiometry
and OAE testing confirmed significant hearing loss.
Patients reporting subjective hearing impairment in the
AL group did not have abnormal hearing test results. In
the AP group, only the reported hearing loss by one
patient on day 90 corresponded to significantly impaired
audiometry and OAE results; in this patient malaria rein-
fection was diagnosed.
Pure tone audiometry
Air conduction hearing thresholds were compared for a
standard range of frequencies from 0.125 to 8 kHz. Bone
conduction thresholds were also measured at all time
points in order to exclude a possible conductive hearing
loss. Figure 2 shows similar mean hearing levels at day 0
(baseline) for all groups and all frequencies. In the Q
group, a hearing loss affecting all frequencies is evident on
day 7 and has disappeared by day 28. Otherwise, no sig-
nificant changes of the mean hearing thresholds com-
pared to day 0 were evident, except for some slight general
improvement in all groups.
When comparing the mean 4-tone-average (0.5, 1, 2, 3
kHz) as the clinically most significant frequency range, a
similar picture emerges (Figure 3). Multivariate analysis of
the 4-tone-average revealed a strong interaction between
the factors group and time on day 7, confirming the tem-
porary threshold shift caused by quinine. Multivariate
analysis of the mean average of higher frequencies (4, 6
and 8 kHz) reveals the same effect.
Table 3: Symptoms and clinical signs
Drug Group Quinine Atovaquone-proguanil Artemether-lumefantrine
n = 30 30 30 23 30 30 30 26 30 30 30 28
day 0 7 2 8 9 007 2 8 9 0 0 72 89 0
Hearing Problem 0 9 1 00101 1210
Tinnitus 2 8 3 04611 6420
Vertigo 6 0 1 08100 4310
Imbalance 1 0 0 00000 0000
Spontaneous nystagmus 0 0 0 00000 0000
Provoked nystagmus 0 0 0 00000 0000
Pathologic head rotation test 1 0 0 00000 1000
Impaired coordination 0 0 0 00000 0000
Fever 2 4052 2 3 2 3 1 2 6 0 1 2
Shivering 2 3012 2 6 4 3 1 2 1 1 1 1
Headache 30 5 5 2 30 10 6 3 30 7 4 2
Nausea 2 1120 1 7 1 1 0 2 2 0 0 4
Diarrhea 4 0 0 02110 3000
Vomiting 1 0 0 01000 1000
Anorexia 2 0 1 03000 0000
Abdominal pain 1 0 0 00000 1000
Arthralgia 3 0 0 03000 1000
Myalgia 1 0 0 00000 0000
Chest pain 0 0 0 00100 0000
Cough 0 1 0 00100 0000Malaria Journal 2008, 7:179 http://www.malariajournal.com/content/7/1/179
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According to the ASHA criteria for ototoxicity [24], there
was no evidence of persistent hearing loss in any treat-
ment group.
Otoacoustic emissions
The average DP threshold level of the Q group on day 7 is
markedly elevated from baseline, corroborating the pure
tone audiometry data (Figure 4). Multivariate analysis
reveals a significant effect of time on the DP threshold lev-
els for day 7 and day 28. This is reflected in the general
improvement of DP thresholds for these time points
when compared to baseline. The three treatment groups
do not behave differently, except on day 7 when a signifi-
cant combined effect of time and group is visible as the Q
ototoxicity.
Transitory evoked otoacoustic emissions (TEOAE) could
be elicited on both ears in all examinations, except for
three patients in the Q group on day 7, in whom TEOAE
could not be detected in either ear, and who suffered a
transient hearing loss greater than 30 dB.
Brainstem evoked response audiometry
Interpeak latencies (IPL) were calculated for the I–V, I–III
and III–V intervals. In all groups, IPL I–V were shorter on
day 0 than on later time points (Figure 5). The difference
in IPL I–III between the AL group and the other two
groups on day 28 was limited to the right ear. However,
only one patient in the AL group had a potentially clini-
cally relevant interaural difference of IPL I–III greater than
10% on day 28, which disappeared by day 90. No perma-
nent drug-related prolongation of interpeak latencies
occurred.
By comparison of these measurements with normative
data (2.49 ms for IPL I–III, 2.16 ms for IPL III–V, 4.45 ms
for IPL I–V; [25] ), IPL III–V was prolonged in one Q
treated patient (left ear) on day 28, but not on day 90.
pure tone hearing levels Figure 2
pure tone hearing levels. Audiometrically determined mean hearing levels on day 0, 7, 28 and 90. Transient hearing loss in 
the quinine treated group is observed on day 7. No permanent hearing loss in either group occurred. Measuring unit of y-axis 
is dB nHL.
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Discussion
The controversy about artemisinins and ototoxicity in
humans has only recently been investigated by Toovey et
al [5]. The authors compared audiometric data from 150
adult construction site employees who have been treated
with AL for uncomplicated malaria with 150 matched
controls who neither suffered malaria nor received arte-
mether. Significant hearing loss over the term of their
employment was found in frequencies between 1 and 8
kHz. This was judged to be irreversible, because the time
between treatment and exit audiogram (mean = 163 days,
range 3–392 days) did not correlate with the degree of
hearing loss [26]. However, possible confounding factors
like the influence of noise exposure in these construction
site workers or the lack of a control group of malaria
patients treated with other antimalarials, make it difficult
to establish a causal relationship between hearing loss
and AL therapy from this retrospective evaluation.
Animal studies demonstrated that parenteral admininis-
tration of lipophilic artemisinin derivatives – such as arte-
mether – can induce focal brainstem lesions including
auditory and vestibular pathways (reviewed in [27] ). Oral
preparations, however, have different pharmacokinetics
and do not achieve as high plasma concentrations [28],
suggesting that the prolonged presence of artemisinin
upon slow release from oil-based intramuscular formula-
tions and the relatively high doses used in animal studies
are the main cause of neurotoxicity in laboratory animals.
A post-mortem study examined brains of patients who
had died of severe malaria and had received either intra-
muscular artemether (n = 6) or intravenous quinine (n =
15) in doses exceeding currently deployed regimens and
found no evidence of the typical artemisinin lesions
observed in animal studies [29]. However, since median
time from admission to death in the artemether group was
Pure tone average 0,5–3 kHz Figure 3
Pure tone average 0,5–3 kHz. Plot of means +/- 1 standard deviation of the pure tone average at 0.5, 1, 2, and 3 kHz for 
day 0, 7, 28 and 90 stratified by therapy group (solid line: Quinine, dashed line: Atovaquone/proguanil, dotted line: Artemether/
lumefantrine). As depicted in the graph a slight improvement of PTA was found during the first 28 days after treatment in the 
Atovaquone/proguanil and Artemether/lumefantrine group unlike the Quinine group, which experienced a marked but tran-
sient hearing loss measured on day 7. On day 90, the differences of means were larger than those on day 28, which can be 
explained as an effect of the long-term observation. No permanent hearing loss in either group occurred. The results pre-
sented in the graph are strongly confirmed by multivariate analysis. Measuring unit of y-axis is dB nHL.
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only 76.5 h, delayed neurotoxicity may not have been
detected, as suggested from in vitro studies [30].
Detailed neurological data are provided by Price et al: of
more than 1,000 patients above five years of age treated
with artemether or artesunate (alone or in combination
with mefloquine) and examined on days 2, 7 and 28 post-
treatment, no patient developed deafness (assessed by
tuning-fork test) or permanent neurological abnormali-
ties.
A retrospective study carried out in Vietnam [8] compared
337 subjects who had received from two to 21 courses
(median = 2) of either artemisinin or artesunate with 108
controls from the same village. Even though 20% of the
subjects had received cumulative doses of ≥ 500 mg/kg
artemisinin (or the adjusted equivalent of artesunate),
which might be more than in any other group of people
in the world, the authors found no evidence of a drug
effect on screening audiometry (testing for hearing loss ≥
40 dB), brainstem evoked auditory potential latencies or
neurological examination. Similar results were obtained
in two case-control studies from Thailand in 79 subjects
treated at least twice with oral artesunate or artemether [9]
and in 68 patients who had been treated with AL [7].
A recent study in 15 adult volunteers with experimental
falciparum malaria treated with AL could not detect any
ototoxicity by using conventional and evoked response
audiometry, but did not compare artemisinins to other
antimalarials [31].
This study is the first randomized clinical trial directly
comparing ototoxicity of AL with other antimalarial
drugs. Quinine has since long been known to cause hear-
ing loss and tinnitus (cinchonism). Generally, this side-
effect is reported to be reversible within about 24 hours
[32], although some case reports have described perma-
nent hearing impairment associated with quinine treat-
ment. In guinea pigs given large doses of quinine, there is
degeneration of the organ of Corti which begins with loss
of the external hair cells, and may further affect the stria
vascularis and inner hair cells.
The Q and AP group can be viewed as a "positive control"
and "negative control", respectively. Furthermore, an
DPOAE level 1,5–6 kHz Figure 4
DPOAE level 1,5–6 kHz. Mean DPOAE estimated hearing levels +/- 1 standard deviation at 1.5, 2, 3, 4 and 6 kHz (solid line: 
Quinine, dashed line: Atovaquone/proguanil, dotted line: Artemether/lumefantrine). Estimated hearing levels are elevated in 
the quinine treated group on day 7. No permanent elevation in estimated hearing levels in either group occurred, which is con-
firmed by multivariate analysis. Measuring unit of y-axis is dB nHL.
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Interpeak latencies I–V, I–III, III–V Figure 5
Interpeak latencies I–V, I–III, III–V. Mean interpeak latencies between Jewett waves I, III and V +/- 1 standard deviation 
(solid line: Quinine, dashed line: Atovaquone/proguanil, dotted line: Artemether/lumefantrine). Interpeak latencies in all groups 
are shorter on day 0, when patients have elevated body temperature. The difference in IPL I–III between the Artemether/lume-
fantrine group and the other two groups is limited to the right ear. No permanent drug-related prolongation of interpeak 
latencies occurs, as confirmed by multivariate analysis.
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attempt was made to evaluate the study population's
audiovestibular systems as comprehensively as possible,
including air and bone conduction audiometry for defi-
nite exclusion of conductive hearing loss and otoacoustic
emissions for direct objective assessment of cochlear func-
tion. In addition to the assessment on day 28, patients
were examined on a late time-point (day 90) to check for
reversibility of any potential hearing loss. In consequence,
day 90 data could be biased by the fact that not all patients
were available for the day 90 examinations (7 in the qui-
nine group, 4 in the AP group and 2 in the AL group).
However, a separate analysis including only patients who
completed follow-up until day 90 showed results similar
to those depicted.
The relatively low numbers of positive clinical findings or
complaints related to the audiovestibular system (Table
3) makes comparison across groups difficult. Neverthe-
less, the transient quinine ototoxicity on day 7 is clearly
correlated with an elevated number of patients complain-
ing of hearing problems. When comparing the time
course in the overall patient population, there is a rela-
tively high proportion of patients who complain of tinni-
tus on day 0 and of tinnitus and perceived hearing loss on
day 7. The symptom vertigo which is prevalent primarily
on day 0 does not seem to be of vestibular origin, since the
clinical vestibular function tests are not significantly
abnormal in either group. There were no relevant neuro-
logical impairments detected. For practical reasons, this
study did not incorporate objective vestibular function
tests. Rotatory and caloric vestibular tests necessitate a
considerable amount of specialized equipment. Vestibu-
lar evoked myogenic potentials (VEMP) recording is now
emerging as a reliable tool to assess otolith function and
could be useful in future studies, since this can be done
with a standard BERA equipment. The air conduction
hearing thresholds of our patients show no detrimental
influence of AL in comparison to the other two study
drugs. In contrast, a significant temporary hearing loss
was observed in quinine treated patients on day 7. The
observed general tendency of improved hearing levels on
later time points in comparison to day 0 could be due to
either a learning process or a direct transient negative
effect of malaria on hearing or a lack of concentration in
the acutely ill patients on day 0. The relatively high thresh-
olds in the lower frequencies probably reflect the presence
of some ambient noise.
Otoacoustic emissions are sound signals resulting from
the mechanical action of outer hair cells in the organ of
Corti. By stimulating the cochlea simultaneously with two
signals of specific frequencies and sound pressure levels,
distortion product otoacoustic emissions at a third spe-
cific frequency are elicited and can be measured. By plot-
ting stimulus (input) sound pressure levels versus DP
(output) levels, a DP threshold value can be calculated,
i.e. the lowest stimulus level producing an outer hair cell
response. Since outer hair cell responses are needed for
physiological hearing perception at the hearing threshold,
this DP threshold correlates very well with the subjective
hearing threshold. It, therefore, provides an objective esti-
mate of hearing levels in patients with mild to moderate
cochlear hearing loss [17].
Overall, the objective otoacoustic emission data largely
parallel the subjective audiometric data. It is therefore
demonstrated that the elevated hearing levels in audio-
metric measurements were due to the known transient
cochleotoxic effect of quinine.
DP thresholds of later time points are generally lower than
those on day 0 (except for the quinine group on day 7).
This cannot be due to a lack of concentration on day 0 nor
to a learning curve, since this test directly assesses outer
hair cell function without the need for patients' coopera-
tion. The fact that the DP threshold levels are slightly
lower than the pure tone audiometer thresholds is proba-
bly due to some ambient noise that could not be avoided
in lack of a truly sound-proof chamber.
From the pattern of artemisinin-induced focal brainstem
lesions in animal studies, it can be expected that an anal-
ogous lesion in humans would lead to a prolongation of
the interpeak latency of Jewett waves III–V. The observed
shorter interpeak latencies on day 0 are associated with
elevated body temperature, a correlation previously
described [33,34]. There was no permanent drug-related
latency prolongation in the patients treated with AL. A
prolonged interpeak or absolute latency, compared with
normative data, occurred in none of the AL-treated
patients.
Conclusion
In conclusion, this study could not detect any detrimental
effect of a standard oral regimen of AL on peripheral hear-
ing or brainstem auditory pathways in patients with
uncomplicated falciparum malaria as assessed by pure
tone audiometry, otoacoustic emission recording and
brainstem evoked response audiometry. In contrast, this
study clearly detects the transient quinine induced hearing
loss due to temporary outer hair cell dysfunction. These
results therefore support the continued use of oral artem-
isinine based combination therapy for uncomplicated
malaria.
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